We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
西那卡塞对血液透析患者继发性甲状旁腺功能亢进症的疗效观察.
- Authors
黄 琳; 李 慧; 张 艳; 唐红进; 童昌军
- Abstract
Objective To explore the clinical efficacy of cinacalcet hydrochloride (Gepin) in the treatment of maintenance hemodialysis (MHD) patients with secondary hyperparathyroidism (SHPT).Methods We selected 40 patients with MHD treatment ≥ 3 months coupled with SHPT from the Blood Purification Center of our hospital,which were randomly divided into cinacalcet hydrochloride group and conventional treatment with 20 cases each.The changes in the levels of blood Ca2+,P3-,PTH,etc. were compared before and after 3 months to evaluate the clinical efficacy.Results Compared with the observation group,the effective rate and total effective rate of the cinacalcet group were higher than those of the observation group (P < 0.05).The comparison of before and after the treatment of cinacalcet:Ca2+ (2.43±0.18) vs. (2.29±0.17) mmol/L (P <0.05),P3- (1.85±0.48) vs. (1.41±0.32) mmol/L (P <0.05),Ca2+ * P3- (55.60±14.33) vs. (39.99±8.92) mg2/dL2 (P <0.05),PTH (798.21±198.67) vs. (379.05±175.22) pg/L (P <0.05). The observation group only:PTH (668.77±245.15) vs. (519.11±176.77) pg/L (P <0.05),and there was no significant difference in Ca2+ and P3- (P >0.05).After the treatment of xylacaxide group,the efficacy of PTH was significantly higher than that in the observation group (379.05±175.22) vs. (519.11±176.77) pg/L (P <0.05).Conclusion Cinacalcet hydrochloride can effectively reduce the levels of Ca2+,P3-,PTH, etc.in MHD patients accompanied by SHPT,and improve bone mineral metabolism disorders.
- Publication
Journal of Modern Medicine & Health, 2021, Vol 37, Issue 18, p3066
- ISSN
1009-5519
- Publication type
Article
- DOI
10.3969/j.issn.1009-5519.2021.18.003